JP2012136540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012136540A5 JP2012136540A5 JP2012038079A JP2012038079A JP2012136540A5 JP 2012136540 A5 JP2012136540 A5 JP 2012136540A5 JP 2012038079 A JP2012038079 A JP 2012038079A JP 2012038079 A JP2012038079 A JP 2012038079A JP 2012136540 A5 JP2012136540 A5 JP 2012136540A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- use according
- medicament
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 201000007455 central nervous system cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004267 taurolidine Drugs 0.000 claims 2
- 229950007343 taurultam Drugs 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16912799P | 1999-12-06 | 1999-12-06 | |
| US16912299P | 1999-12-06 | 1999-12-06 | |
| US16912899P | 1999-12-06 | 1999-12-06 | |
| US60/169,127 | 1999-12-06 | ||
| US60/169,122 | 1999-12-06 | ||
| US60/169,128 | 1999-12-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541495A Division JP5027369B2 (ja) | 1999-12-06 | 2000-12-06 | 腫瘍を治療する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153442A Division JP6234340B2 (ja) | 1999-12-06 | 2014-07-29 | 腫瘍を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012136540A JP2012136540A (ja) | 2012-07-19 |
| JP2012136540A5 true JP2012136540A5 (OSRAM) | 2013-05-16 |
| JP5829948B2 JP5829948B2 (ja) | 2015-12-09 |
Family
ID=27389609
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541496A Withdrawn JP2003515558A (ja) | 1999-12-06 | 2000-12-06 | 腫瘍を治療するためのメチロール含有化合物の使用 |
| JP2001541495A Expired - Fee Related JP5027369B2 (ja) | 1999-12-06 | 2000-12-06 | 腫瘍を治療する方法 |
| JP2012038079A Expired - Fee Related JP5829948B2 (ja) | 1999-12-06 | 2012-02-24 | 腫瘍を治療する方法 |
| JP2014153442A Expired - Fee Related JP6234340B2 (ja) | 1999-12-06 | 2014-07-29 | 腫瘍を治療する方法 |
| JP2016149539A Pending JP2016188244A (ja) | 1999-12-06 | 2016-07-29 | 腫瘍を治療する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541496A Withdrawn JP2003515558A (ja) | 1999-12-06 | 2000-12-06 | 腫瘍を治療するためのメチロール含有化合物の使用 |
| JP2001541495A Expired - Fee Related JP5027369B2 (ja) | 1999-12-06 | 2000-12-06 | 腫瘍を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153442A Expired - Fee Related JP6234340B2 (ja) | 1999-12-06 | 2014-07-29 | 腫瘍を治療する方法 |
| JP2016149539A Pending JP2016188244A (ja) | 1999-12-06 | 2016-07-29 | 腫瘍を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US6964959B2 (OSRAM) |
| EP (3) | EP2332542B1 (OSRAM) |
| JP (5) | JP2003515558A (OSRAM) |
| AT (1) | ATE339207T1 (OSRAM) |
| AU (2) | AU784538B2 (OSRAM) |
| CA (3) | CA2393252A1 (OSRAM) |
| DE (1) | DE60030770T2 (OSRAM) |
| ES (2) | ES2438535T3 (OSRAM) |
| WO (2) | WO2001039763A2 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030027818A1 (en) | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US20030225067A1 (en) * | 1999-06-04 | 2003-12-04 | Ruediger Stendel | Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs |
| US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US20020098164A1 (en) | 2000-10-27 | 2002-07-25 | Redmond H. Paul | Treatment of tumor metastases and cancer |
| EP1797884B1 (en) * | 1999-12-06 | 2013-09-11 | Geistlich Pharma AG | Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme |
| CA2393252A1 (en) * | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
| CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| US20020081339A1 (en) * | 2000-12-22 | 2002-06-27 | Philippe Menei | Treatment of inoperable tumors by stereotactic injection of microspheres |
| GB0104383D0 (en) * | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
| CA2441016A1 (en) * | 2001-03-15 | 2002-09-26 | Paul Calabresi | Taurine compounds |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
| WO2003028642A2 (en) * | 2001-10-01 | 2003-04-10 | Rhode Island Hospital, A Lifespan Partner | Methods of inhibiting metastases |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| ATE333298T1 (de) * | 2002-03-21 | 2006-08-15 | Geistlich Soehne Ag | Vorrichtung für behandlung eines tumors im zentralen nervensystem |
| CA2499738A1 (en) * | 2002-09-24 | 2004-04-08 | Novartis Ag | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
| JP5346148B2 (ja) * | 2003-03-28 | 2013-11-20 | エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー | 抗新生物性組成物および治療方法 |
| US20050008684A1 (en) * | 2003-07-10 | 2005-01-13 | Claus Herdeis | Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition |
| US8236794B2 (en) | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| JP2007537200A (ja) * | 2004-05-14 | 2007-12-20 | ハンス−ディートリヒ・ポラシェグ | タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護 |
| CA2570501A1 (en) * | 2004-06-18 | 2006-01-26 | Gergely Szakacs | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
| DK1904093T3 (en) * | 2005-07-19 | 2018-09-03 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with BMP-4 |
| WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| US20100291173A1 (en) * | 2006-09-05 | 2010-11-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of improving renal function |
| WO2008029264A2 (en) * | 2006-09-07 | 2008-03-13 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treating bone cancer |
| EP2240175B1 (en) * | 2008-02-11 | 2013-01-02 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Compounds with mdr1-inverse activity |
| DE102010010360A1 (de) * | 2010-03-05 | 2011-09-08 | Gamptec Gmbh | Formulierungen von Taurolidin und Verfahren zu seiner Herstellung |
| EP2575783B1 (en) | 2010-06-01 | 2017-01-11 | Geistlich Pharma AG | Methods and compositions for oral pharmaceutical therapy |
| CA2812845A1 (en) | 2010-09-27 | 2012-04-05 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
| US9241943B2 (en) | 2012-06-18 | 2016-01-26 | Geistlich Pharma Ag | Oxathiazine derivatives as antibacterial and anticancer agents |
| CA2930359C (en) * | 2013-12-06 | 2022-03-01 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
| US20170100407A1 (en) * | 2015-10-07 | 2017-04-13 | Cormedix Inc. | Skin-penetrating formulation of taurolidine |
| US20190381058A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| CA3010981C (en) * | 2016-01-11 | 2024-09-17 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
| WO2018126133A1 (en) * | 2016-12-29 | 2018-07-05 | Cormedix Inc. | Skin-penetrating formulation of taurolidine |
| CN109929804B (zh) * | 2017-12-15 | 2020-10-16 | 天津医科大学肿瘤医院 | 一种人卵巢癌细胞系及其制备方法和应用 |
| KR20210050544A (ko) * | 2018-08-28 | 2021-05-07 | 코르메딕스, 인코포레이티드 | 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료 |
| CA3111015A1 (en) * | 2018-08-28 | 2020-03-05 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| AU2019331913B2 (en) * | 2018-08-31 | 2025-06-26 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| WO2020234833A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Method for treating, preventing, inhibiting or reducing cytokine release |
| US20220323452A1 (en) | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1124285A (en) | 1964-10-06 | 1968-08-21 | Geistlich Soehne Ag | Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them |
| GB1408010A (en) | 1972-11-20 | 1975-10-01 | Geistlich Soehne Ag | Sulphamoylphenyl-imidazolidinones |
| GB1557163A (en) | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
| US4107305A (en) | 1975-08-04 | 1978-08-15 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Treatment of endotoxaemia |
| GB1588110A (en) | 1978-05-31 | 1981-04-15 | Geistlich Soehne Ag | Pharmaceutical compositions for the treatment of scars |
| US4192302A (en) * | 1978-09-12 | 1980-03-11 | Boddie Arthur W | Hepatic isolation and perfusion circuit assembly |
| JPS5598170A (en) * | 1979-01-18 | 1980-07-25 | Mitsui Toatsu Chem Inc | 5-fluorouracil derivative and its preparation |
| US4337251A (en) * | 1979-05-09 | 1982-06-29 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of avoiding and removing adhesions |
| CA1190855A (en) | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
| GB8328111D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
| GB8328074D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compositions |
| GB8328073D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
| US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| US5573771A (en) * | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
| GB8827986D0 (en) * | 1988-11-30 | 1989-01-05 | Geistlich Soehne Ag | Chemical product |
| US5819748A (en) * | 1988-11-30 | 1998-10-13 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Implant for use in bone surgery |
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| EP0521225B1 (en) * | 1991-07-04 | 1994-10-12 | Hawe Neos Dental Dr. H. v. Weissenfluh SA | Pharmaceutical preparation for treatment of periodontitis, containing clavulanic acid |
| US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| GB9216155D0 (en) | 1992-07-30 | 1992-09-09 | Geistlich Soehne Ag | Treatment of dentoalveolar infections |
| FR2728790B1 (fr) * | 1994-12-29 | 1997-01-24 | Cird Galderma | Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial |
| US5954687A (en) * | 1995-04-28 | 1999-09-21 | Medtronic, Inc. | Burr hole ring with catheter for use as an injection port |
| US5976822A (en) | 1995-05-18 | 1999-11-02 | Coulter International Corp. | Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis |
| GB9600426D0 (en) | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| DE19606897C2 (de) * | 1996-02-13 | 2002-08-29 | Geistlich Soehne Ag | Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren |
| WO1998052572A1 (en) * | 1997-05-22 | 1998-11-26 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| GB9716219D0 (en) | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6011030A (en) | 1997-09-22 | 2000-01-04 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating symptoms of microbial infection or sepsis |
| US5972933A (en) | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
| US6117868A (en) | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| CA2393252A1 (en) * | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
| US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
-
2000
- 2000-12-06 CA CA002393252A patent/CA2393252A1/en not_active Abandoned
- 2000-12-06 CA CA2393159A patent/CA2393159C/en not_active Expired - Lifetime
- 2000-12-06 WO PCT/US2000/033104 patent/WO2001039763A2/en not_active Ceased
- 2000-12-06 EP EP10012266.2A patent/EP2332542B1/en not_active Expired - Lifetime
- 2000-12-06 US US09/731,214 patent/US6964959B2/en not_active Expired - Lifetime
- 2000-12-06 US US09/730,923 patent/US6429224B1/en not_active Expired - Lifetime
- 2000-12-06 CA CA2696185A patent/CA2696185C/en not_active Expired - Lifetime
- 2000-12-06 EP EP00983965A patent/EP1246617B1/en not_active Expired - Lifetime
- 2000-12-06 ES ES06019082.4T patent/ES2438535T3/es not_active Expired - Lifetime
- 2000-12-06 JP JP2001541496A patent/JP2003515558A/ja not_active Withdrawn
- 2000-12-06 AT AT00983965T patent/ATE339207T1/de active
- 2000-12-06 DE DE60030770T patent/DE60030770T2/de not_active Expired - Lifetime
- 2000-12-06 EP EP00983966A patent/EP1248625A2/en not_active Withdrawn
- 2000-12-06 AU AU20650/01A patent/AU784538B2/en not_active Ceased
- 2000-12-06 ES ES10012266.2T patent/ES2531547T3/es not_active Expired - Lifetime
- 2000-12-06 US US09/730,666 patent/US6521616B2/en not_active Expired - Lifetime
- 2000-12-06 WO PCT/US2000/033103 patent/WO2001039762A2/en not_active Ceased
- 2000-12-06 AU AU20649/01A patent/AU784539B2/en not_active Ceased
- 2000-12-06 JP JP2001541495A patent/JP5027369B2/ja not_active Expired - Fee Related
-
2002
- 2002-08-05 US US10/212,401 patent/US6703413B2/en not_active Expired - Lifetime
- 2002-11-21 US US10/301,263 patent/US6995164B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/350,313 patent/US20060135513A1/en not_active Abandoned
-
2012
- 2012-02-24 JP JP2012038079A patent/JP5829948B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-29 JP JP2014153442A patent/JP6234340B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-29 JP JP2016149539A patent/JP2016188244A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012136540A5 (OSRAM) | ||
| Zhang et al. | Prodrug strategy for cancer cell-specific targeting: A recent overview | |
| Hong et al. | Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells | |
| JP2016517888A5 (OSRAM) | ||
| JP2012517427A5 (OSRAM) | ||
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| IL222120A (en) | Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs | |
| TN2012000608A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| JP2009286795A5 (OSRAM) | ||
| JP2014526456A5 (OSRAM) | ||
| JP2011157399A5 (OSRAM) | ||
| NZ712696A (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
| JP2016528162A5 (OSRAM) | ||
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| JP2016040288A5 (OSRAM) | ||
| Zhao et al. | Epithelial-mesenchymal transition in cancer: Role of the IL-8/IL-8R axis | |
| JP2014534269A5 (OSRAM) | ||
| Li et al. | Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference | |
| MX2014006629A (es) | Inhibidores de cinasa. | |
| WO2016127168A3 (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos |